Summary.-The experiments aimed at evaluating the optimal parameters in the chemo-immunotherapeutic treatment of the L1210 lymphoid leukaemia grafted to [female BALB/c (H2d) x male DBA/2 (H2d)]Fl hybrid mice, hereafter referred to as CDF1 mice.
Summary.-The experiments aimed at evaluating the optimal parameters in the chemo-immunotherapeutic treatment of the L1210 lymphoid leukaemia grafted to [female BALB/c (H2d) x male DBA/2 (H2d)]Fl hybrid mice, hereafter referred to as CDF1 mice.
In vitro irradiation of leukaemic ascites cells by X-or y-rays and subsequent inoculation in mice showed that optimum immunogenicity is radiation dose-dependent.
Grafting mice with l07 leukaemic ascites cells irradiated at optimum dose (80 GyXor y-rays) delays mortality of the animals when challenged later with untreated L1210 cells, but is unable to cure mice. By contrast, specific immunoprophylaxis induced by Micrococcus, complement-triggering polysaccharides or BCG and irradiated leukaemic cells was able to protect mice against grafts of 104 L1210 cells. The i.p. route was notably superior to the i.v. route.
When mice bearing advanced L1210 tumour were treated by chemotherapy (12 mg/ kg of BCNU) on Day 6 5 after grafting 104 L1210 cells and subsequently treated by immunotherapy, a very high percentage (up to 90o%) of mice with 108 leukaemic cells could be cured by repeated 1 mg injections of bacterium or polysaccharide, and challenge with irradiated leukaemic cells was unnecessary.
Because of the high cure rate obtained, the very regular response pattern and the non-pathogenicity, the bacterium Micrococcus Iysodeikticus would seem a promising new candidate for chemo-immunotherapeutic antitumour strategies.
THE BCG STRAIN of Mycobacterium bovis has become a popular agent for immunotherapy of cancer. However, the general use of BCG is made difficult because of many disadvantages: BCG can cause ulceration, pyrexia, abnormal liver function, tuberculosis and, in a few reported cases, death or even enhancement of tumour growth Spark et al., 1973; Mansell & Krementz, 1973) .
Micrococcus lysodeikticus is a nonpathogenic and easy-to-eliminate (substrate of lysozyme) Gram-positive bacterium, that elicits the production of large amounts of antibodies of restricted heterogeneity and clonal dominance in rabbits (Van Hoegaerden et al., 1975) and mice (Verloes et al., 1977a; b) . Since antimicrococcus antibodies are directed against carbohydrates (Wikler, 1975) and bind to certain lymphocytes De Baetselier et al., 1977) and to several tumour-cell types (L1210 lymphoid cells, Ehrlich carcinoma cells) but not to erythrocytes (Verloes et al., 1979a) , they are believed to act on cells in a similar way to the lectins but with greater discrimination and less t To wloom requests for reprints and correspondence sbould be addressed. toxicity for normal cells . The interaction of antimicrococcus antibodies with receptors on neoplastic cells was confirmed by others, and a cellcycle-stage dependency was established (Grooten & Hamers, 1979) .
Although a single injection of Micrococcus suspended in incomplete Freund adjuvant does not display an adjuvant effect for protein antigens (Kotani et al., 1975) , we have demonstrated that multiple Micrococcus injections, like live BCG injections, elicit a comparable number of plaque-forming cells to sheep erythrocytes, whereas Micrococcus-treated mice showed markedly less toxicity than BCG-treated animals (Verloes et al., 1979b) . We have also previously demonstrated that Micrococcus lysodeikticus is able to activate complement by the alternative pathway (Verloes et al., 1977b) and the importance of this phenomenon in inflammation is well documented (Bianco et al., 1976; Ward, 1967 , Schorlemmer et al., 1976 (Mathe et al., 1977) or effective (Kataoka et al., 1978) , special attention was paid to determine the experimental parameters that yield an optimal antitumour response.
MATERIAL AND METHODS
Micrococcus lysodeikticus (ML), cell wall of ML, cell-wall-conjugated chitin and chitin were prepared as earlier described .
Bacillus Calmette-Guerin.-Vials containing 100 mg of lyophilized Bacillus CalmetteGuerin (BCG-SP) for scarification were purchased from the Pasteur Institute, Brussels. After reconstitution with the appropriate diluent and further dilution in Hanks' balanced salt solution (HBSS) the suspension was kept at 4°C and used within 2 weeks.
Zymosan A .-The cell wall ofSaccharomyces cerevisiae (yeast) was commercially available (Lot No. 34C-2650-Sigma Company) . Insoluble cell walls were boiled for 1 h in 0.9% NaCl solution, washed x 3 with PBS and centrifuged at 3000 g for 20 min.
Inulin. Animals.-Female [female BALB/c (H2d) x male DBA/2 (H2d)] F1 hybrid mice (CDF1) were purchased from Charles River Breeding Laboratories, Calco, Italy. Those mice were stored 3 weeks in an isolation room and used before they were 10 weeks old. Animals weighing 19-23 g were used.
Tumour. L1210 leukaemia was originally induced in female DBA/2 mice with methylcholanthrene in ether (Law et al., 1949 MST over control mice respectively for the 80, 120 and 17OGy schedules, as seen in Table I . In order to compare the effect of the irradiation source on lethality and immunogenicity of L1210 cells, the same experiment was performed using an Euratom X-ray apparatus (250 kV, 12 mA, 0 95 Gy/min). Whereas 107 unirradiated cells killed mice 5 50 days + 0-71 after grafting, 4OGy-irradiated leukaemic cells killed mice 14 90 days+ ± 91 after challenge. No mortality was seen with the other grafts. When survivors were rechallenged with 104 cells i.p., we found a 53, 48 and 27% increase in MST over controls respectively, as seen in Table I II, the i.p. route generated a more effective immunoprotection. Our data also indicate that immunoresponse leads to an all-ornone reaction; it is able to induce longterm survivors but unable to prolong significantly mean survival of the other immunized and tumour-bearing mice. This fact does not weaken the results, especially since the number of animals surviving to Day 90 is very high. There were slight differences in immunoprotection rates for zymosan (86%), Micrococcus (71%) and BCG (86%). From these experiments, we also learned that the i.p. route definitely yielded better results, and consequently was used in the following chemo-immunotherapeutic trial. Chemo-immunotherapy: drug design and experimental control These experiments were conducted to maximize the chemotherapeutic response of an antitumour drug therapy by immunotherapy. We concentrated our efforts on advanced (terminal) disease for which treatment is initiated several days before the expected death day of controls. For that purpose, CDF1 mice were given i.p. 104 L1210 cells on Day 0 and the tumour was allowed to grow and spread. On Day 6-5, when the tumour burden is considered to reach 108 cells (Cantrell et al., 1976) and treatment by bacterial immunoadjuvant only (BCG or ML) proved to be unsuccessful, mice received one single i.p. injection of BCNU (12 mg/kg) and were subsequently treated by immunotherapy on Day 8, either by 107 irradiated (80 Gy y-rays) in vivo-grown L1210 cells combined with 1 mg of bacterium or polysaccharide, or by 1 mg of bacterium or polysaccharide alone. This experimental protocol for chemotherapy was adopted from Cantrell et al. (1976) . All untreated control mice died after 10-22 days + 0 44, whereas mice treated by chemotherapy died after 19-80 days+ 4 34 and mice treated by chemotherapy and 107 irradiated cells died after 20-80 days+ 5-07. No long-term survivors were recorded.
As seen in Table III In a final set of experiments, we have investigated whether inoculation of 107 leukaemic cells irradiated at optimal dose (80 Gy y-rays) could improve the chemoimmunotherapeutic schedule described above. As illustrated in Figs 3 Figs 1-4) .
We conclusively demonstrated that Micrococcus, zymosan A and inulin applied after BCNU therapy yielded an appreciably greater percentage (P < 0.005) of cured mice than leukaemic mice given BCNU chemotherapy only. ii. 1. (Fig. 3) or on Days 11, 14, 17 and 20 (Fig. 4) . Statistical evaluations were determined by x2 distribution for difference from mice given BCNU only. NS = not significant.
wE- 
DISCUSSION
Many antigenic tumours such as L1210 leukaemia are poorly immunogenic (Cantrell et al., 1976) and require stimuli to elicit immune responses (Glynn et al., 1963) . As more effective stimuli, we have used BCG, Micrococcus and structurally related complement-triggering polysaccharides.
Previous studies indicated that pretreatment of mice with those agents alone was insufficient to provide immunoprotection against tumour grafting (Verloes et al., 1978) . We have therefore compared the effect of different doses of X-or y-rays on lethality of in vivo-grown (Huget et al., 1977) , it would be interesting to investigate whether the kinetics of immunosuppression affects similarly i.v. or i.p. challenged mice. Although chloro-ethyl-nitrosoureas constitute an established class of important antitumour agents, repeated administration of BCNU to human patients may produce a dramatic marrow toxicity (Schein et al., 1978) . Therefore, applying successful immunotherapy after effective chemotherapy instead of maintenance chemotherapy, is one possibility for counteracting long-lasting drug toxicity in humans and mice, and reducing the probability of in vivo selection of drug-resistant neoplastic cell clones, thus offering a chance of cure. When tumour-bearing mice were treated (once) by BCNU chemotherapy (Verloes et al., 1977b) by the polymorphonuclear leucocytes and the subsequent exocytosis of lysosomal enzymes (i.e. lysozyme) by these cells (Schorlemmer et al., 1976) . Probably this also accounts for the observation that repeated lmg Micrococcus injections enhance 5-fold the number of direct plaqueforming cells to sheep erythrocytes, whereas one injection displays no effect (Verloes et al., 1979b) . By using low doses of BCNU with nonspecific (without irradiated cells) immunotherapy, we were able to cure up to 9000 of mice bearing 1 08 leukaemic cells by repeated lmg injections of bacteria or polysaccharides. Highest survival scores were obtained with Micrococcus lysodeikticus. Furthermore, although the data presented do not demonstrate clearly the superiority of Micrococcus over zymosan or inulin chemo-immunotherapy, we must mention that antimicrococcus antibodies selectively recognize epitopes on tumour cells such as L1210 cells and that repeated 1mg injections of BCG( to intact mice produced a considerable loss of weight which did not occur after Micrococcus lysodeikticus (Verloes et al., 1979b) . The fact that the therapeutic values of Micrococcus and zymosan A were rather schedule-independent, whereas values obtained with BCG were critically influenced by timing and antigen presentation, strengthens the interest in Micrococcus. It is also obvious that repeated imnmunological treatments are more effective than a single administration, and that rechallenge with irradiated leukaemic cells is not strictly required for this working schedule. Very probably, effective cytotoxic chemotherapy provided immunocompetent cells with immunogenic material, and the immune system was subsequently triggered by complementactivating polysaccharides or bacteria. In this perspective, it is worth mentioning that a similar prevailing condition can be created by intratumour cytotoxic chemotherapy (followed by intratumour immunotherapy) of inoperable cancers where it is impossible to obtain antigens.
The high cure rates obtained, the regular therapeutic response (at least as good or better than with BCG and zymosan) the absence of toxicity and the non-pathogenicity of Micrococcus lysodeikticus promote this easy-to-eliminate bacterium (substrate of lysozyme) as an attractive candi-.)08 date for new chemo-immunotherapeutic antitumour strategies.
